Literature DB >> 19034335

Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients.

Ana M Ramos1, Marta Albalate, Silvia Vázquez, Carlos Caramelo, Jesús Egido, Alberto Ortiz.   

Abstract

UNLABELLED: Disturbances in bone and mineral metabolism are common in chronic kidney disease (CKD) patients. Most studies have been performed in hemodialysis and there is less information on non-dialysis patients, on the coexistence of other risk factors and on the achievement of more recent and stringent guidelines. Cross sectional study of analytical mineral and bone parameters in 125 incident patients (creatinine clearance <60 ml/min) in a monographic CKD clinic. Evaluation after one year of follow-up in 69 patients. Progression of CKD was associated with significant increased levels of phosphate, calcium x phosphate and iPTH and decreased calcium and 1,25 dihydroxyvitamin D. Levels of 25-hydroxyvitamin D were unchanged, but lower than recommended. Phosphate correlated negatively with 1,25-dihydroxivitamin D and creatinine clearance, and positively with iPTH. At every stage of CKD, most patients had PTH values outside recommended limits. More than 69% CKD 3 and CKD 4 patients had higher than recommended PTH levels. Above recommended phosphate levels were present in 25% of CKD 4 and 47% of CKD 5 patients. Most of these had associated high LDL-cholesterol. Higher than recommended calcium levels were more prevalent than low calcium and there was a high prevalence (31%) of vascular calcification. One year of intervention improved the percentage of patients with controlled calcium or iPTH, but not phosphate.
CONCLUSIONS: In incident CKD patients there is a high prevalence of out-of-target mineral and bone analytical parameters. The currently authorized therapeutic arsenal for these patients may not be adequate to deal with the problem.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034335     DOI: 10.1038/ki.2008.543

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  7 in total

1.  High prevalence of winter 25-hydroxyvitamin D deficiency despite supplementation according to guidelines for hemodialysis patients.

Authors:  Emilio González-Parra; Pablo Justo Avila; Ignacio Mahillo-Fernández; Carolina Lentisco; Carolina Gracia; Jesús Egido; Alberto Ortiz
Journal:  Clin Exp Nephrol       Date:  2012-05-29       Impact factor: 2.801

2.  Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate.

Authors:  Emilio González-Parra; Álvaro Aceña; Óscar Lorenzo; Nieves Tarín; María Luisa González-Casaus; Carmen Cristóbal; Ana Huelmos; Ignacio Mahíllo-Fernández; Ana María Pello; Rocío Carda; Ignacio Hernández-González; Joaquín Alonso; Fernando Rodríguez-Artalejo; Lorenzo López-Bescós; Alberto Ortiz; Jesús Egido; José Tuñón
Journal:  J Bone Miner Metab       Date:  2015-08-23       Impact factor: 2.626

3.  Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease.

Authors:  S Geng; Z Kuang; P L Peissig; D Page; L Maursetter; K E Hansen
Journal:  Osteoporos Int       Date:  2019-05-31       Impact factor: 4.507

Review 4.  Secreted klotho and chronic kidney disease.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 5.  Klotho and kidney disease.

Authors:  Ming-Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  J Nephrol       Date:  2010 Nov-Dec       Impact factor: 3.902

6.  Determination of NF-κB and RANKL levels in peripheral blood osteoclast precursor cells in chronic kidney disease patients.

Authors:  Gülcan Güneş; Nil Doğruer Ünal; Gülçin Eskandari; Ahmet Kiykim; Özlem Bölgen Çimen; Gülhan Temel; Mehmet Burak Y Çimen
Journal:  Int Urol Nephrol       Date:  2018-04-11       Impact factor: 2.370

7.  Predictors of early postoperative hypocalcemia in patients with secondary hyperparathyroidism undergoing total parathyroidectomy.

Authors:  Wei Gong; Yaqi Lin; Yu Xie; Zilu Meng; Yudong Wang
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.